Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Vistagen Therapeutics FY2026 Q3 Earnings Call - AI-led analysis targets placebo response to steer PALISADE-4
Vistagen used this quarter to close out the randomized portion of PALISADE-3 and double down on understanding why PALISADE-3 showed a higher placebo response than prior studies. Management is running ...
- Completed the randomized portion of PALISADE-3 as previously guided.
- Company is performing cross-study AI/ML analyses to identify covariates and predictors of placebo and drug response across PALISADE studies.
- PALISADE-3 showed a higher placebo response versus PALISADE-2, prompting analytical and operational responses.
- +11 more takeaways
Coincheck Group N.V. Q3 FY2026 Earnings Call - 3iQ Acquisition and CEO Transition Signal Shift to Global Institutional Push
Coincheck reported a stable quarter despite broad crypto price weakness, delivering $915 million in revenue, $9.1 million of Adjusted EBITDA and $2.6 million of net income for Q3 FY2026. Management hi...
- Total revenue was $915 million in Q3 FY2026, up sequentially and up 17% year over year to JPY 143.5 billion, per management commentary.
- Adjusted EBITDA was $9.1 million in Q3, down slightly from $9.5 million in Q2, and down 38% year over year to JPY 1,428 million.
- Net income was $2.6 million for the quarter versus $2.3 million in Q2; the prior-year quarter included large listing and transaction costs that produced a loss.
- +12 more takeaways
Vertex Pharmaceuticals Fourth Quarter 2025 Earnings Call - Povetacicept Emerges as a Potential Renal Franchise Anchor with BLA Rolling and Phase III on Track
Vertex closed 2025 with solid top-line momentum, a diversified commercial mix, and a clear pivot toward building a renal franchise around povetacicept. Financials were strong — $3.2 billion in Q4 and ...
- Q4 2025 revenue was $3.2 billion, up 10% year-over-year; full year 2025 revenue was $12.0 billion, up 9% versus 2024.
- Vertex expects 2026 revenue of $12.95 billion to $13.1 billion, implying 8%–9% growth, and guides for non-CF products to contribute $500 million or more.
- CF remains the cash engine, with full year 2025 CF revenue up 7% globally and the franchise serving over 77,000 patients on Vertex therapies.
- +17 more takeaways
Yelp Q4 2025 Earnings Call - AI and services growth buoy profits as restaurants and retail lag
Yelp closed 2025 with modest top-line growth and stronger profitability, driven by services, data licensing, and a rapid roll out of AI features. Full-year net revenue rose 4% to $1.46 billion, net in...
- Full-year 2025 net revenue was $1.46 billion, up 4% year-over-year, with net income of $146 million, up 10% YoY and diluted EPS of $2.24, up 19% YoY.
- Adjusted EBITDA for 2025 was $369 million, a 25% margin, up 3% year-over-year; 2025 free cash flow was a record $324 million.
- Q4 2025 net revenue fell 1% YoY to $360 million; Q4 net income was $38 million, down 10% YoY; Q4 Adjusted EBITDA was $86 million, down 15% YoY.
- +12 more takeaways
Pinterest Q4 2025 Earnings Call - Record Users, Revenue Lag Tied to Retail Tariffs and Urgent Sales Overhaul
Pinterest closed Q4 2025 with a user base that headline writers will envy, but a revenue beat the company itself called insufficient. The platform reported 619 million MAUs, its tenth straight quarter...
- 619 million MAUs in Q4 2025, up 12% year over year, marking 10 consecutive quarters of record-high users.
- Pinterest reports roughly 80 billion monthly searches, most visual, and 1.7 billion monthly outbound clicks, with over half of searches classified as commercial intent.
- Q4 2025 revenue was $1.319 billion, up 14% year over year (13% constant currency), a result management said fell short of the company’s potential.
- +12 more takeaways
Dexcom Q4 2025 Earnings Call - G7 15-Day rollout lifts margins as Medicare Type 2 non-insulin coverage looms
Dexcom closed 2025 on a healthier note: Q4 revenue rose 13% to $1.26 billion, full-year results beat the high end of guidance, and the company finished with about $2 billion in cash after settling con...
- Q4 2025 revenue $1.26 billion, up 13% year over year; U.S. revenue $892 million, international $368 million (18% growth).
- Full-year revenue finished above the high end of Dexcom's most recent guidance; 2026 revenue guide is $5.16 billion to $5.25 billion, +11% to +13%.
- Gross profit in Q4 was $799.8 million, or 63.5% of revenue, a ~400 basis point improvement year over year and more than 200 basis points sequentially. 2026 gross margin guidance is 63% to 64%, with management targeting 200 to 300 basis points of expansion.
- +12 more takeaways
Bio-Rad Q4 2025 Earnings Call - ddPCR Traction and Supply-Chain Margin Pressures
Bio-Rad closed 2025 with mixed execution. Revenue was essentially flat for the year at $2.583 billion, Q4 sales rose to $693 million driven by diagnostics, while life science remained soft as academic...
- Q4 2025 net sales were $693 million, up 3.9% reported and up 1.7% on a currency neutral basis versus Q4 2024.
- Full year 2025 revenue was $2.583 billion, essentially flat year-over-year on a currency neutral basis.
- Life Science Q4 sales were $268 million, down 2.6% reported and down 4% currency neutral, hurt by weak academic and early-stage biotech instrument demand.
- +13 more takeaways
Applied Materials Q1 FY2026 Earnings Call - AI-Led Ramp Means >20% Semi-Equipment Growth, Clean-Room Capacity Now the Governor
Applied reported a clean beat in Q1 FY2026 with $7.0 billion revenue and $2.38 non-GAAP EPS, then doubled down on a very bullish setup: the company expects its semiconductor equipment business to grow...
- Q1 results: revenue $7.0 billion (upper end of guidance), non-GAAP EPS $2.38, non-GAAP gross margin 49.1% (up 20 bps YoY).
- Company guidance for Q2: revenue $7.65 billion ± $500 million; non-GAAP EPS $2.64 ± $0.20; non-GAAP gross margin ~49.3%; non-GAAP OpEx ~ $1.415 billion.
- Applied expects its semiconductor equipment business to grow more than 20% in calendar 2026, with demand weighted to the second half of the year and momentum expected to carry into 2027.
- +17 more takeaways
Capstone Green Energy Q3 FY2026 Earnings Call - Record Adjusted EBITDA and ramp toward data center megawatt opportunity
Capstone reported a clear operational inflection in Q3 FY2026: revenue of $26.8 million, up 33% year over year, and a record adjusted EBITDA of $5.1 million, marking the seventh straight quarter of po...
- Q3 revenue $26.8 million, up 33% year over year; year-to-date revenue $83 million, up 42% versus prior year.
- Record quarterly adjusted EBITDA of $5.1 million, seventh consecutive quarter of positive adjusted EBITDA, YTD adjusted EBITDA > $12.3 million, exceeding all of FY2025 by over $4 million.
- Gross profit $10.4 million and gross margin expanded to 39%, a 14 point improvement versus prior year, driven by favorable product mix, DFMA cost-outs, and the Cal Microturbine distributor acquisition.
- +12 more takeaways
10x Genomics Q4 2025 Earnings Call - Flex APEX adoption drives consumables volume even as instrument sales lag amid tight research funding
10x Genomics closed Q4 with $166 million in revenue and finished 2025 at $599 million of revenue, excluding $44 million of upfront patent settlement revenue. The quarter showed a tale of two businesse...
- Q4 revenue $166 million, beating the high end of guidance; full year 2025 revenue $599 million, excluding $44 million of upfront patent litigation settlement revenue.
- Company set 2026 revenue guidance at $600 million to $625 million, which implies roughly 0% to 4% growth year over year when excluding the 2025 settlement revenue.
- Consumables show strength: total consumables revenue up 6% in Q4; single-cell consumables up 3% with reaction volumes growing double digits, and spatial consumables up 14% driven by Xenium.
- +12 more takeaways